Why carry out this study?

Bacteremia associated with infection can result in substantial morbidity and mortality.

This exploratory analysis assessed efficacy and safety outcomes in patients with Gram-negative bacteremia treated with ceftazidime-avibactam or comparator across five phase 3, randomized, controlled, multi-center trials in adults with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI)/pyelonephritis, hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP).

What was learned from the study?

Clinical and microbiological responses in the bacteremia subset were generally similar to those in the overall set.

The pattern of adverse events in patients with Gram-negative bacteremia was similar between treatment groups and consistent with the known safety profile of ceftazidime-avibactam.

This analysis provides supportive evidence of the efficacy and safety of ceftazidime-avibactam in patients with Gram-negative bacteremia associated with cIAI, cUTI/pyelonephritis, or HAP/VAP.